Congestive heart failure acute pharmacotherapy

Jump to navigation Jump to search
Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure acute pharmacotherapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure acute pharmacotherapy

CDC on Congestive heart failure acute pharmacotherapy

Congestive heart failure acute pharmacotherapy in the news

Blogs on Congestive heart failure acute pharmacotherapy

Directions to Hospitals Treating Congestive heart failure acute pharmacotherapy

Risk calculators and risk factors for Congestive heart failure acute pharmacotherapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: acute decompensated heart failure, ADHF, flash pulmonary edema

Overview

Acute heart failure can occur in the setting of a new onset heart failure or worsening of an existing chronic heart failure (also known as acute decompensated heart failure, flash pulmonary edema, ADHF). ADHF presents with acute shortness of breath due to the development of pulmonary edema (the rapid accumulation of fluid in the lung). Other signs and symptoms of ADHF include hypotension with impaired and organ perfusion manifested by worsening renal function, altered mentation and cold clammy extremities. ADHF associated with a poor prognosis if not treated aggressively. Like chronic heart failure therapy, the goal is to improve symptoms but unlike chronic therapy the other goals are to improve oxygenation and hemodynamic stability. The mainstays of the acute medical treatment in acute decompensated congestive heart failure include oxygen to improve hypoxia, diuresis to reduce both preload and intravascular volume and vasodilators to reduce afterload. Some of the mainstays of chronic heart failure therapy are not initiated acutely (ACE inhibtors,beta blockers and digoxin).

General Recommendations

Hospitalization

Hospitalization is required for the management of the patient with ADHF with the following signs, symptoms and laboratory abnormalities: [1]

Telemetry and Monitoring

The patient should be admitted to a level of care that allows for constant electrocardiographic monitoring given the risk of arrhythmias and frequent vital signs.

  • The heart rhythm and oxygen saturation should be monitored continuously.
  • Is and Os (intake and output) should be monitored carefully. A daily target should be established (for example the patient should be one liter negative for the day) and diuretic dosing should be adjusted to achieve this target.
  • Daily weights should be obtained using the same scale at the same time of the day, usually before the patient has eaten, and after they have first voided in the morning. Often times Is and Os measurements will underestimate insensible losses that occur through the lungs.
  • The BUN and creatinine, serum sodium(to detect hyponatremia which carries a poor prognosis), chloride, bicarbonate (to detect contraction alkalosis) and serum potassium (to detect hypokalemia as a result of diuresis and which can precipitate arrhythmias) should be monitored daily. Potassium and magnesium should be repeated as needed following diuresis.

Medical Therapy

Systolic Versus Diastolic Heart Failure

The management of the patient with acute decompensated heart failure depends upon whether the patient has acute decompensated systolic heart failure or acute decompensated diastolic heart failure. Both forms of acute decompensated heart failure are treated with oxygen and vasodilator therapy and diuresis. Importantly, inotropic agents that increase contractility are not indicated in the patient with acute decompensated diastolic heart failure while they are important for the patient with acute decompensated systolic heart failure. While beta blocker initiation is relatively contraindicated in acute decompensated systolic heart failure, control of tachycardia is very useful in the patient with diastolic heart failure to prolong left ventricular filling time. While the initiation of ACE inhibitors may not be recommended in acute decompensated systolic heart failure, ACE inhibition may be of benefit in acute decompensated diastolic heart failure.

Treatment Goals

Management Plan

Oxygen

Diuretics

  • Diuretics reduce preload and reduce intravascular volume. Intravenous diuretics are often required in the acute setting. If high doses of furosemide are inadequate, boluses or continuous infusions of bumetanide may be preferred. These loop diuretics may be combined with thiazide diuretics such as oral metolazone or intravenous chlorthiazide for a synergistic effect. Intravenous preparations are preferred because of more predictable absorption. When a patient is extremely fluid overloaded, they can develop intestinal edema as well, which can affect enteral absorption of medications.

Nitroglycerine

Morphine

More Aggressive Pharmacotherapy

Arrhythmias

Atrial Fibrillation

Atrial fibrillation can cause acute decompensation of heart failure due to an increase in heart rate and oxygen demands, and conversely acute decompensation of heart failure can precipitate atrial fibrillation due to left atrial dilation and increased wall stress. Thus, atrial fibrillation and acute decompensated heart failure are often intimately related, and the successful management of atrial fibrillation is often critical to the success of reversing the acute decompensation.

In the patient with acute decompensated heart failure, rate control of atrial fibrillation is the mainstay of arrhythmia therapy. Obviously agents that have a negative inotropic effect such as beta blockers and non-dihydropyridine calcium channel blockers are relatively contraindicated in the management of acute decompensated systolic heart failure. Intravenous diltiazem does not have a negative inotropic effect and is often used for rate control. Short acting esmolol is sometimes used. Digoxin has a very narrow therapeutic/toxic window, it's onset of action is relatively delayed, and it is often not used.

If a patient is in cardiogenic shock, then cardioversion can be considered in the patient with atrial fibrillation, however in the absence of severe hemodynamic compromise it should be noted that atrial fibrillation will often recur in this setting. Thus, cardioversion is not particularly helpful in the absence of profound hemodynamic compromise. If the patient is going to be cardioverted, unfractionated heparin should be administered.

References

  1. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN (2010). "HFSA 2010 Comprehensive Heart Failure Practice Guideline". Journal of Cardiac Failure. 16 (6): e1–194. doi:10.1016/j.cardfail.2010.04.004. PMID 20610207. Retrieved 2013-04-29. Unknown parameter |month= ignored (help)
  2. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J (2008). "Noninvasive ventilation in acute cardiogenic pulmonary edema". N. Engl. J. Med. 359 (2): 142–51. doi:10.1056/NEJMoa0707992. PMID 18614781. Unknown parameter |month= ignored (help)
  3. Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD (2006). "Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis". Lancet. 367 (9517): 1155–63. doi:10.1016/S0140-6736(06)68506-1. PMID 16616558. Unknown parameter |month= ignored (help)
  4. Weng CL; Zhao YT; Liu QH; et al. (2010). "Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema". Ann. Intern. Med. 152 (9): 590–600. doi:10.1059/0003-4819-152-9-201005040-00009. PMID 20439577. Unknown parameter |month= ignored (help); Unknown parameter |author-separator= ignored (help)


Template:WikiDoc Sources